CAR-T Meeting 2022 | Exciting developments in CAR-T therapies in and beyond hematological malignancies
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the latest advances in chimeric antigen receptor T-cell (CAR-T) therapies. CAR-Ts have changed the treatment landscape of hematological malignancies and are now being evaluated in earlier lines of therapy. There is a lot of ongoing work in developing CAR-Ts for solid tumors, as well as in other conditions including cardiac fibrosis, and autoimmune and infectious diseases. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Transcript (edited for clarity)
Of course, what’s happening now, is that in most of the indications CAR-T therapies are moving to earlier lines of therapies. So in several indications, CAR-Ts are challenging high-dose chemotherapy and autologous stem cell transplantation. I think it was also very impressive and interesting and motivating for young scientists and clinicians to really work in the CAR-T field, is that CAR-Ts are also clearly moving into the treatment of solid tumors...
Of course, what’s happening now, is that in most of the indications CAR-T therapies are moving to earlier lines of therapies. So in several indications, CAR-Ts are challenging high-dose chemotherapy and autologous stem cell transplantation. I think it was also very impressive and interesting and motivating for young scientists and clinicians to really work in the CAR-T field, is that CAR-Ts are also clearly moving into the treatment of solid tumors. There are several studies now ongoing, new approaches. And also beyond oncology, autoimmune disorders, cardiac fibrosis, infectious diseases, are all new targets for redirected CAR-Ts. So I think the field is definitely expanding and the options for CAR-T therapy have clearly increased. And also the basic science behind CAR-Ts is really developing at a very rapid pace. So this year’s CAR T-cell meeting was extremely stimulating and motivating, I think for all people, all clinicians, all basic scientists involved in CAR-T therapy.
Read more...
